Prucalopride: Safety, efficacy and potential applications

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 1, 2012, Pages 23-30

  Quigley, Eamonn M M ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

Colonic motilty; Constipation; Irritable bowel syndrome; Prokinetic; Prucalopride

Indexed keywords

PLACEBO; PRUCALOPRIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ARRHYTHMOGENESIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; IRRITABLE COLON; NAUSEA; PRIORITY JOURNAL; REVIEW;

EID: 84855541533     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11423706     Document Type: Review

References (48)

1. Boeckxstaens G.E. Bartelsman J.F. Lauwers L. Tytgat G.N. (2002) Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 97: 194–197.
2. Bouin M. Plourde V. Boivin M. Riberdy M. Lupien F. Laganière M. et al. (2002) Rectal distension testing in patients with the irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 122: 1771–1777.
3. Bouras E.P. Camilleri M. Burton D.D. McKinzie S. (1999) Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 44: 682–686.
4. Bouras E.P. Camilleri M. Burton D.D. Thomforde G. McKinzie S. Zinsmeister A.R. (2001) Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 120: 354–360.
5. Boyce M. Kerstens R. Beyens G. Ausma J. Vandeplassche L. (2009) Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials [abstract]. Gastroenterology 136(Suppl. 1): T1265.
6. Brandt L.J. Chey W.D. Schiller L.R. Schoenfeld P.S. Spiegel B.M. Talley N.J. et al. (2009) An evidence-based systematic review of the management of irritable bowel syndrome. Am J Gastroenterol 104: S1–S35.
7. Brandt L.J. Schoenfeld P. Prather C.M. Quigley E.M.M. Schiller L.R. Talley N.J. (2005) Evidence-based position statement on the management of chronic constipation in North America. Am J Gastroenterol 100(Suppl. 1): S5–S21.
8. Camilleri M. Beyens G. Kerstens R. Robinson P. Vandeplassche L. (2009) Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 21: e1256–e117.
9. Camilleri M. Bharucha A.E. di Lorenzo C. Hasler W.L. Prather C.M. Rao S.S. et al. (2008 a) American Neurogastroenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil 20: 1269–1282.
10. Camilleri M. Hasler W.L. Parkman H.P. Quigley E.M. Soffer E. (1998) Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology 115: 747–762.
11. Camilleri M. Kerstens R. Rykx A. Vandeplassche L. (2008 b) A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358: 2344–2354.
12. Camilleri M. van Outryve M.J. Beyens G. Kerstens R. Robinson P. Vandeplassche L. (2010) Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation - follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 32: 1113–1123.
13. Chan K.Y. de Vries R. Leijten F.P. Pfannkuche H.J. van den Bogaerdt A.J. Danser A.H. et al. (2009) Functional characterization of contractions to tegaserod in human isolated proximal and distal coronary arteries. Eur J Pharmacol 619: 61–67.
14. Coremans G. Kerstens R. de Pauw M. Stevens M. (2003) Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 67: 82–89.
15. de Schryver A.M. Andriesse G.I. Samsom M. Smout A.J. Gooszen H.G. Akkermans L.M. (2002) The effects of the specific 5HT (4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 16: 603–612.
16. Di Palma J.A. Cleveland M.V. McGowan J. Herrera J.L. (2007) A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol 102: 1964–1971.
17. Drossman D.A. Li Z. Andruzzi E. Temple R.D. Talley N.J. Thompson W.G. et al. (1993) US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 38: 1569–1580.
18. Drossman D.A. Chey W.D. Johanson J.F. Fass R. Scott C. Panas R. et al. (2009) Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 29: 329–341.
19. Dubois D. Gilet H. Viala-Danten M. Tack J. (2010) Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil 22: e54–e63.
20. Emmanuel A.V. Kamm M.A. Roy A.J. Antonelli K. (1998) Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut 42: 511–516.
21. Emmanuel A.V. Roy A.J. Nicholls T.J. Kamm M.A. (2002) Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 16: 1347–1356.
22. Emmanuel A.V. Tack J. Quigley E.M. Talley N.J. (2009) Pharmacological management of constipation. Neurogastroenterol Motil 21(Suppl. 2): 41–54.
23. Johanson J.F. Drossman D.A. Panas R. Wahle A. Ueno R. (2008 a) Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 27: 685–696.
24. Johanson J.F. Morton D. Geenen J. Ueno R. (2008 b) Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 103: 170–177.
25. Johnston J.M. Kurtz C.B. Macdougall J.E. Lavins B.J. Currie M.G. Fitch D.A. et al. (2010) Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 139: 1877–1886.
26. Krogh K. Jensen M.B. Gandrup P. Laurberg S. Nilsson J. Kerstens R. et al. (2002) Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 37: 431–436.
27. Lembo A.J. Kurtz C.B. Macdougall J.E. Lavins B.J. Currie M.G. Fitch D.A. et al. (2010) Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 138: 886–895.
28. Lin H.C. Prather C. Fisher R.S. Meyer J.H. Summers R.W. Pimentel M. et al. (2005) Measurement of gastrointestinal transit. Dig Dis Sci 50: 989–1004.
29. Lindberg G. Hamid S. Malfertheiner P. Thomsen O. Bustos Fernandez L. Garisch J. et al. (2011) World Gastroenterology Organisation Global Guidelines. Constipation: a global perspective. http://www.worldgastroenterology.org/assets/export/userfiles/05_constipation.pdf (accessed 11 July 2011).
30. Longstreth G.F. Thompson W.G. Chey W.D. Houghton L.A. Mearin F. Spiller R.C. (2006) Functional bowel disorders. Gastroenterology 130: 1480–1491.
31. McKee D.P. Quigley E.M.M. (1993) Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1: Definition of IBS and colonic motility. Dig Dis Sci 38: 1761–1772.
32. Müller-Lissner S. Rykx A. Kerstens R. Vandeplassche L. (2010) A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 22: 991–998.
33. Odunsi S.T. Camilleri M. (2009) Selected interventions in nuclear medicine: gastrointestinal motor functions. Semin Nucl Med 39: 186–194.
34. Poen A.C. Felt-Bersma R.J. van Dongen P.A. Meuwissen S.G. (1999) Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 13: 1493–1497.
35. Potet F. Bouyssou T. Escande D. Baro I. (2001) Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J Pharmacol Exp Ther 299: 1007–1012.
36. Quigley E.M. (2003) Current concepts of the irritable bowel syndrome. Scand J Gastroenterol Suppl 237: 1–8.
37. Quigley E.M.M. (2011) Cisapride. What can we learn from the rise and fall of a prokinetic?. J Dig Dis 12: 147–156.
38. Quigley E.M.M. Bergmann J.-F. Bytzer P. Fried M. Hunt R. Hungin A.P.S. et al. (2007) An evidence-based approach to the management of irritable bowel syndrome in Europe. Eur J Gastroenterol Hepatol 19(Suppl 1): S1–S37.
39. Quigley E.M. Vandeplassche L. Kerstens R. Ausma J. (2009) Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation–a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 29: 315–328.
40. Sanger G.J. Quigley E.M.M. (2010) Constipation, IBS and the 5-HT4 receptor: what role for prucalopride?. Clin Med Insights: Gastroenterology 3: 21–33.
41. Sloots C.E. Poen A.C. Kerstens R. Stevens M. de Pauw M. van Oene J.C. et al. (2002) Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 16: 759–767.
42. Sloots C.E. Rykx A. Cools M. Kerstens R. de Pauw M. (2010) Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 55: 2912–2921.
43. Sonnenberg A. Koch T.R. (1989) Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci 34: 606–611.
44. Tack J. Ausma J. Kerstens R. Vandeplassche L. (2008) Safety and tolerability of prucalopride (Resolor®) in patients with chronic constipation: pooled data from three pivotal phase III studies [abstract]. Gastroenterology 134: A530–A531.
45. Tack J. Müller-Lissner S. Stanghellini V. Boeckxstaens G. Kamm M.A. Simren M. et al. (2011) Diagnosis and treatment of chronic constipation – a European perspective. Neurogastroenterol Motil 23: 697–710.
46. Tack J. van Outryve M. Beyens G. Kerstens R. Vandeplassche L. (2009) Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58: 357–365.
47. Talley N.J. O'Keefe E.A. Zinsmeister A.R. Melton L.J. 3rd (1992) Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology 102: 895–901.
48. von der Ohe M.R. Camilleri M. (1992) Measurement of small bowel and colonic transit: indications and methods. Mayo Clin Proc 67: 1169–1179.